In ErbB2 (a driver oncogene) positive breast cancer cells, ECD controls ErbB2 mRNA export and stability by regulating the decreased expression of herstatin (a tumor suppressor splice variant) and increased expression of the Δ16HER2 variant (a pro-oncogenic splice variant) [16,70–72]. This evidence concerns the gene ERBB2 and breast carcinoma.